As previously reported, The U.S. Preventive Services Task Force (USPSTF) released its updated draft PrEP grading adding long-acting Cabotegravir (CAB-LA), the every-other-month injectable PrEP medication to the A rating already given to daily oral PrEP in 2019, making it possible to get a new HIV prevention option to people who would rather take a shot 6 times a year than a daily pill. According to the rating, CAB-LA must be made available without cost-sharing to people with employer-based health coverage and ACA approved health plans.

PrEP4All, with input from partners and community members, applauds the move and submitted public comments in an effort to support access for those most in need of PrEP. There is much work to be done to hold insurance companies accountable to cover the full cost of PrEP for consumers, but this a necessary step toward effective advocacy towards full PrEP coverage for all.